Health
Emyria to seek approval for trial evaluating MDMA to treat PTSD – Stockhead
Nine years after a potentially groundbreaking Australian clinical trial evaluating the use of the psychoactive drug molly to treat post-traumatic stress disorder…
Link copied toclipboard
Nine years after a potentially groundbreaking Australian clinical trial evaluating the use of the psychoactive drug molly to treat post-traumatic stress disorder was rejected on ethics grounds, an ASX-listed drug development company is taking another crack at it.
Emyria (ASX:EMD) announced this morning that in partnership with Mind Medicine Australia it would seek approval for a major clinical trial testing the use of MDMA to alleviate treatment-resistant PTSD.
Emyria managing…
-
Noosa News18 hours agoPill checking to resume in Queensland months after government axed funding
-
Business21 hours agoWhy Austal, Boss Energy, Harvey Norman, and NextDC shares are charging higher today
-
Business22 hours agoASX shares are expensive. Here’s why you should be buying anyway
-
Noosa News22 hours agoNew Queensland Translink app receives scathing reviews as old app is retired